Autoimmunity BioSolutions

Coming – April 14

Deploying Precision Medicine To Treat Rheumatoid Arthritis

Date and Time

April 14

–

12:00 PM ET / 9:00 AM PT

Details will be provided upon RSVP approval

About this Event

Autoimmunity BioSolutions (ABS) is taking a revolutionary approach to treating autoimmune disease that’s rooted in precision medicine, rather than broad immunosuppression.

Today, 30–50% of patients with rheumatoid arthritis, lupus, Type 1 diabetes and other autoimmune diseases, don’t respond to the current standard of care. The common thread among these patients is an elevated soluble IL-7 receptor (sIL7R).

ABS has developed a proprietary biomarker platform that identifies likely non-responders and enables a precision, “immuno-corrective” approach designed to fix the underlying biological driver. The treatment is based around a proprietary monoclonal antibody that targets sIL7R and can turn patients who don’t respond to treatments like Humira and Xeljanz into those who do.

ABS therapies are designed to work in combination with existing standards of care, improving response rates without increasing immunosuppression risk, a key limitation in current treatments.

Join our online event to hear ABS CEO, Eugene Williams, share how represents an opportunity to make a real difference to the estimated 25 million people with Autoimmune Diseases who currently don’t respond to treatment.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.